Report Overview

Indian Glaucoma market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 11% during the forecast period.

Glaucoma, the third-largest ophthalmic submarket in India, is mainly a pharmaceutical market, and the main driver of revenue growth will be better access to glaucoma medicines. Market Scope forecasts that Indias glaucoma market will increase to $XX million by 2028 at a CAGR of approximately 11%. The diagnostic equipment market is the second largest ophthalmic market in India and is expected to reach nearly $XX million in 2028. Growth will be driven by expansion of telemedicine, advancements to automate medical records, enhanced imaging technologies, consolidations of hospitals, and a rise in Indian companies entering the market. The increasing incidence and prevalence of glaucoma is expected to drive the anti-glaucoma drugs market growth. Effective implementation of government health plans is the core reason for the improvement in healthcare access in India.



Market Drivers

The increasing prevalence of glaucoma cases among the elderly population will bolster the market growth. Glaucoma is highly prevalent in patients with diabetes and other eye disorders, such as age-related macular degeneration (AMD), cataract and dry eye. In line with this, the rising geriatric population, which is more susceptible to such ailments, is creating a positive outlook for the market growth. Furthermore, increasing health consciousness among the masses and rising preference for laser glaucoma surgery is also driving the market growth. The increasing screen time of gadgets such as laptops and smartphones are resulting in the rising incidence of glaucoma. Increasing product launches and products under pipelines will accelerate the growth of this market. Drug recalls can contribute as a restraining factor in the market growth along with devices that offers long term benefits, efficacy, and lower side effects.